Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
rabies mab CBB 1 is mainly used for passive immunization of patients bitten or scratched by
rabies or other animals carrying rabies virus, this study mainly studies the safety,
tolerability, pharmacokinetics, neutralizing antibody activity and immunogenic
characteristics of rabies mAb CBB 1 in healthy adults
Phase:
Early Phase 1
Details
Lead Sponsor:
Changchun BCHT Biotechnology Co.
Collaborators:
Anning City First People's Hospital Beijing Contreke Statistical Technology Co., LTD Military Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine